» Articles » PMID: 36169175

Altered Expression of the Locus and Mitochondrial Respiratory Complexes in Adrenocortical Carcinoma

Abstract

Abnormalities of the insulin‑like growth factor 2 locus with the overexpression of are frequent findings in adrenocortical carcinoma (ACC). The present study assessed the expression of RNAs and microRNAs (miRNAs/miRs) from the locus using PCR‑based methods in ACC and adrenocortical adenoma (ACA). The results were associated with proteomics data. was overexpressed in ACC, and its expression correlated with that of and hosted by . The downregulated expression of in ACC compared to ACA correlated with expression hosted by . Several proteins exhibited an inverse correlation in expression and were predicted as targets of , or . Subsets of these proteins were differentially expressed between ACC and ACA. These included several proteins involved in mitochondrial metabolism. Among the mitochondrial respiratory complexes, complex I and IV were significantly decreased in ACC compared to ACA. The protein expression of NADH:ubiquinone oxidoreductase subunit C1 (NDUFC1), a subunit of mitochondrial respiratory complex I, was further validated as being lower in ACC compared to ACA and normal adrenals. The silencing of increased NDUFC1 protein expression and reduced both oxygen consumption and glycolysis rates. On the whole, the findings of the present study reveal the dysregulation of the locus and mitochondrial respiration in ACC. These findings may provide a basis for the further understanding of the pathogenesis of ACC and may have potential values for diagnostics and treatment.

Citing Articles

Single-cell transcriptome analysis revealed heterogeneity in glycolysis and identified IGF2 as a therapeutic target for ovarian cancer subtypes.

Ji J, Bi F, Zhang X, Zhang Z, Xie Y, Yang Q BMC Cancer. 2024; 24(1):926.

PMID: 39085784 PMC: 11292870. DOI: 10.1186/s12885-024-12688-7.


The MQRG score: a novel prognostic tool for adrenocortical carcinoma patients based on mitochondrial quality.

Chen T, Wang Y, Chen X, Zheng W, Guo W, Liang Q Front Endocrinol (Lausanne). 2024; 15:1222281.

PMID: 38505747 PMC: 10948487. DOI: 10.3389/fendo.2024.1222281.

References
1.
Fassnacht M, Berruti A, Baudin E, Demeure M, Gilbert J, Haak H . Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015; 16(4):426-35. DOI: 10.1016/S1470-2045(15)70081-1. View

2.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

3.
Marbet P, Klusonova P, Birk J, Kratschmar D, Odermatt A . Absence of hexose-6-phosphate dehydrogenase results in reduced overall glucose consumption but does not prevent 11β-hydroxysteroid dehydrogenase-1-dependent glucocorticoid activation. FEBS J. 2018; 285(21):3993-4004. DOI: 10.1111/febs.14642. View

4.
Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y . Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1998; 83(5):1713-20. DOI: 10.1210/jcem.83.5.4816. View

5.
Juhlin C, Goh G, Healy J, Fonseca A, Scholl U, Stenman A . Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab. 2014; 100(3):E493-502. PMC: 5393505. DOI: 10.1210/jc.2014-3282. View